Researchers from National University Hospital (NUH), National Cancer Institute, Singapore (NCIS), the Yong Loo Lin School of Medicine, National University of Singapore, Duke-NUS Medical School and ...

Six studies were analyzed. Of the total 757 patients with gastric adenocarcinoma, 318 (42.0%) were stage I, 311 (41.0%) were stage II/III, 116 (15.3%) were stage IV, and 22 (2.9%) were undetermined.

OSLO, Norway--(BUSINESS WIRE)--Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced an interim data readout of the Phase 1/2a ...

KEYTRUDA and KEYTRUDA QLEX are the first and only PD-1 inhibitors approved for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma with PD-L1+ tumors ...

Future financings to progress patented hyperthermic technology aimed at improving chemotherapy therapeutic efficacy, tolerability and treatment outcomes for advanced bladder and peritoneal cancers The ...

FDA approved pembrolizumab plus paclitaxel ± bevacizumab for PD-L1 CPS ≥1 platinum-resistant ovarian/fallopian tube/primary peritoneal carcinoma after 1–2 prior systemic therapies. KEYNOTE-B96 ...

Cancer is a universal issue which affects many people around the world. Many will turn to surgery in the hope a surgeon will ...

Gastric cancers commonly spread to the peritoneum. Its presence significantly alters patient prognosis and treatment-intent; however, current methods of peritoneal staging are inaccurate. Peritoneal ...